PubMed:17701343
Annnotations
GlyCosmos6-Glycan-Motif-Image
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 35-44 | Glycan_Motif | denotes | sulfatide | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G95090DW|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G72548RZ|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G40843KY |
| T4 | 185-195 | Glycan_Motif | denotes | sulfatides | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G95090DW|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G72548RZ|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G40843KY |
| T7 | 595-605 | Glycan_Motif | denotes | sulfatides | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G95090DW|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G72548RZ|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G40843KY |
| T10 | 872-881 | Glycan_Motif | denotes | sulfatide | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G95090DW|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G72548RZ|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G40843KY |
| T13 | 942-960 | Glycan_Motif | denotes | galactosylceramide | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G65889KE |
| T14 | 1349-1367 | Glycan_Motif | denotes | galactosylceramide | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G65889KE |
GlyCosmos6-Glycan-Motif-Structure
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 35-44 | https://glytoucan.org/Structures/Glycans/G40843KY | denotes | sulfatide |
| T2 | 35-44 | https://glytoucan.org/Structures/Glycans/G72548RZ | denotes | sulfatide |
| T3 | 35-44 | https://glytoucan.org/Structures/Glycans/G95090DW | denotes | sulfatide |
| T4 | 185-195 | https://glytoucan.org/Structures/Glycans/G40843KY | denotes | sulfatides |
| T5 | 185-195 | https://glytoucan.org/Structures/Glycans/G72548RZ | denotes | sulfatides |
| T6 | 185-195 | https://glytoucan.org/Structures/Glycans/G95090DW | denotes | sulfatides |
| T7 | 595-605 | https://glytoucan.org/Structures/Glycans/G40843KY | denotes | sulfatides |
| T8 | 595-605 | https://glytoucan.org/Structures/Glycans/G72548RZ | denotes | sulfatides |
| T9 | 595-605 | https://glytoucan.org/Structures/Glycans/G95090DW | denotes | sulfatides |
| T10 | 872-881 | https://glytoucan.org/Structures/Glycans/G40843KY | denotes | sulfatide |
| T11 | 872-881 | https://glytoucan.org/Structures/Glycans/G72548RZ | denotes | sulfatide |
| T12 | 872-881 | https://glytoucan.org/Structures/Glycans/G95090DW | denotes | sulfatide |
| T13 | 942-960 | https://glytoucan.org/Structures/Glycans/G65889KE | denotes | galactosylceramide |
| T14 | 1349-1367 | https://glytoucan.org/Structures/Glycans/G65889KE | denotes | galactosylceramide |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-154 | Sentence | denotes | Synthetic sulfogalactosylceramide (sulfatide) and its use for the mass spectrometric quantitative urinary determination in metachromatic leukodystrophies. |
| TextSentencer_T2 | 155-326 | Sentence | denotes | 3-O-Sulfogalactosylceramides (sulfatides) accumulate in the genetic disease metachromatic leukodystrophy which is due to a defect in the catabolic enzyme, arylsulfatase A. |
| TextSentencer_T3 | 327-428 | Sentence | denotes | Clinical diagnosis is usually confirmed by in vitro enzymatic deficiency of arylsulfatase A activity. |
| TextSentencer_T4 | 429-571 | Sentence | denotes | The diagnosis may be complicated because of arylsulfatase A pseudo-deficiencies and another cause of MLD, sphingolipid activator B deficiency. |
| TextSentencer_T5 | 572-698 | Sentence | denotes | As large quantities of sulfatides can be found in the urine in this disease, sulfatiduria appears as an extremely useful test. |
| TextSentencer_T6 | 699-846 | Sentence | denotes | As recently enzyme replacement is underway, the quantitative determination, using an internal standard, appears particularly useful as a follow-up. |
| TextSentencer_T7 | 847-1037 | Sentence | denotes | Thus a non-physiological sulfatide was synthesized for this purpose, i.e. 3-O-sulfo-beta-D-C17 galactosylceramide (3-O-Sulfo-D: -Galactosyl-beta1'-->1-N-Heptadecanoyl-D-erythro-Sphingosine). |
| TextSentencer_T8 | 1038-1170 | Sentence | denotes | It has been prepared through condensation of an azidosphingosine derivative with a protected D-galactopyranosyltrichloroacetimidate. |
| TextSentencer_T9 | 1171-1241 | Sentence | denotes | Reduction of the azide was followed by acylation of a C-17 fatty acid. |
| TextSentencer_T10 | 1242-1453 | Sentence | denotes | The key step was achieved by selective sulfation of the desired hydroxyl group on the sugar residue of the galactosylceramide using the stannylene methodology to give a 3'-sulfated beta-galactosyl C-17 ceramide. |
| T1 | 0-154 | Sentence | denotes | Synthetic sulfogalactosylceramide (sulfatide) and its use for the mass spectrometric quantitative urinary determination in metachromatic leukodystrophies. |
| T2 | 155-326 | Sentence | denotes | 3-O-Sulfogalactosylceramides (sulfatides) accumulate in the genetic disease metachromatic leukodystrophy which is due to a defect in the catabolic enzyme, arylsulfatase A. |
| T3 | 327-428 | Sentence | denotes | Clinical diagnosis is usually confirmed by in vitro enzymatic deficiency of arylsulfatase A activity. |
| T4 | 429-571 | Sentence | denotes | The diagnosis may be complicated because of arylsulfatase A pseudo-deficiencies and another cause of MLD, sphingolipid activator B deficiency. |
| T5 | 572-698 | Sentence | denotes | As large quantities of sulfatides can be found in the urine in this disease, sulfatiduria appears as an extremely useful test. |
| T6 | 699-846 | Sentence | denotes | As recently enzyme replacement is underway, the quantitative determination, using an internal standard, appears particularly useful as a follow-up. |
| T7 | 847-1037 | Sentence | denotes | Thus a non-physiological sulfatide was synthesized for this purpose, i.e. 3-O-sulfo-beta-D-C17 galactosylceramide (3-O-Sulfo-D: -Galactosyl-beta1'-->1-N-Heptadecanoyl-D-erythro-Sphingosine). |
| T8 | 1038-1170 | Sentence | denotes | It has been prepared through condensation of an azidosphingosine derivative with a protected D-galactopyranosyltrichloroacetimidate. |
| T9 | 1171-1241 | Sentence | denotes | Reduction of the azide was followed by acylation of a C-17 fatty acid. |
| T10 | 1242-1453 | Sentence | denotes | The key step was achieved by selective sulfation of the desired hydroxyl group on the sugar residue of the galactosylceramide using the stannylene methodology to give a 3'-sulfated beta-galactosyl C-17 ceramide. |
Glycosmos6-GlycoEpitope
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 942-960 | http://www.glycoepitope.jp/epitopes/EP0074 | denotes | galactosylceramide |
| T2 | 1349-1367 | http://www.glycoepitope.jp/epitopes/EP0074 | denotes | galactosylceramide |
Glycosmos6-MAT
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 626-631 | http://purl.obolibrary.org/obo/MAT_0000058 | denotes | urine |
DisGeNET
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 310-325 | gene:410 | denotes | arylsulfatase A |
| T1 | 215-230 | disease:C0019247 | denotes | genetic disease |
| T2 | 310-325 | gene:410 | denotes | arylsulfatase A |
| T3 | 231-259 | disease:C0023522 | denotes | metachromatic leukodystrophy |
| R1 | T0 | T1 | associated_with | arylsulfatase A,genetic disease |
| R2 | T2 | T3 | associated_with | arylsulfatase A,metachromatic leukodystrophy |
PubmedHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 245-259 | HP_0002415 | denotes | leukodystrophy |
| T1 | 245-259 | HP_0002415 | denotes | leukodystrophy |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 17701343-1#155#170#gene410 | 310-325 | gene410 | denotes | arylsulfatase A |
| 17701343-1#76#104#diseaseC0023522 | 231-259 | diseaseC0023522 | denotes | metachromatic leukodystrophy |
| 155#170#gene41076#104#diseaseC0023522 | 17701343-1#155#170#gene410 | 17701343-1#76#104#diseaseC0023522 | associated_with | arylsulfatase A,metachromatic leukodystrophy |
GlyCosmos15-Glycan
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 942-960 | Glycan | denotes | galactosylceramide | https://api.glycosmos.org/wurcs2image/latest/png/binary/G65889KE |
| T2 | 1349-1367 | Glycan | denotes | galactosylceramide | https://api.glycosmos.org/wurcs2image/latest/png/binary/G65889KE |
Anatomy-MAT
| Id | Subject | Object | Predicate | Lexical cue | mat_id |
|---|---|---|---|---|---|
| T1 | 626-631 | Body_part | denotes | urine | http://purl.obolibrary.org/obo/MAT_0000058 |
mondo_disease
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 123-153 | Disease | denotes | metachromatic leukodystrophies | http://purl.obolibrary.org/obo/MONDO_0009591|http://purl.obolibrary.org/obo/MONDO_0018868 |
| T3 | 215-230 | Disease | denotes | genetic disease | http://purl.obolibrary.org/obo/MONDO_0003847 |
| T4 | 231-259 | Disease | denotes | metachromatic leukodystrophy | http://purl.obolibrary.org/obo/MONDO_0009591|http://purl.obolibrary.org/obo/MONDO_0018868 |
| T6 | 530-533 | Disease | denotes | MLD | http://purl.obolibrary.org/obo/MONDO_0009591|http://purl.obolibrary.org/obo/MONDO_0018868 |
Glycan-GlyCosmos
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 942-960 | Glycan | denotes | galactosylceramide | https://api.glycosmos.org/wurcs2image/latest/png/binary/G65889KE |
| T2 | 1349-1367 | Glycan | denotes | galactosylceramide | https://api.glycosmos.org/wurcs2image/latest/png/binary/G65889KE |
GlyCosmos15-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 137-153 | Phenotype | denotes | leukodystrophies | HP:0002415 |
| T2 | 245-259 | Phenotype | denotes | leukodystrophy | HP:0002415 |
GlyCosmos15-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 123-153 | Disease | denotes | metachromatic leukodystrophies | MONDO:0009591|MONDO:0018868 |
| T3 | 215-230 | Disease | denotes | genetic disease | MONDO:0003847 |
| T4 | 231-259 | Disease | denotes | metachromatic leukodystrophy | MONDO:0009591|MONDO:0018868 |
GlyCosmos15-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 626-631 | Body_part | denotes | urine | http://purl.obolibrary.org/obo/UBERON_0001088 |
GlyCosmos15-Sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-154 | Sentence | denotes | Synthetic sulfogalactosylceramide (sulfatide) and its use for the mass spectrometric quantitative urinary determination in metachromatic leukodystrophies. |
| T2 | 155-428 | Sentence | denotes | 3-O-Sulfogalactosylceramides (sulfatides) accumulate in the genetic disease metachromatic leukodystrophy which is due to a defect in the catabolic enzyme, arylsulfatase A. Clinical diagnosis is usually confirmed by in vitro enzymatic deficiency of arylsulfatase A activity. |
| T3 | 429-571 | Sentence | denotes | The diagnosis may be complicated because of arylsulfatase A pseudo-deficiencies and another cause of MLD, sphingolipid activator B deficiency. |
| T4 | 572-698 | Sentence | denotes | As large quantities of sulfatides can be found in the urine in this disease, sulfatiduria appears as an extremely useful test. |
| T5 | 699-846 | Sentence | denotes | As recently enzyme replacement is underway, the quantitative determination, using an internal standard, appears particularly useful as a follow-up. |
| T6 | 847-1037 | Sentence | denotes | Thus a non-physiological sulfatide was synthesized for this purpose, i.e. 3-O-sulfo-beta-D-C17 galactosylceramide (3-O-Sulfo-D: -Galactosyl-beta1'-->1-N-Heptadecanoyl-D-erythro-Sphingosine). |
| T7 | 1038-1170 | Sentence | denotes | It has been prepared through condensation of an azidosphingosine derivative with a protected D-galactopyranosyltrichloroacetimidate. |
| T8 | 1171-1241 | Sentence | denotes | Reduction of the azide was followed by acylation of a C-17 fatty acid. |
| T9 | 1242-1453 | Sentence | denotes | The key step was achieved by selective sulfation of the desired hydroxyl group on the sugar residue of the galactosylceramide using the stannylene methodology to give a 3'-sulfated beta-galactosyl C-17 ceramide. |
GlyCosmos15-GlycoEpitope
| Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
|---|---|---|---|---|---|
| T1 | 942-960 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | galactosylceramide | http://www.glycoepitope.jp/epitopes/EP0074 |
| T2 | 1349-1367 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | galactosylceramide | http://www.glycoepitope.jp/epitopes/EP0074 |
GlyCosmos15-FMA
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 626-631 | Body_part | denotes | urine | FMA:12274 |
GlyCosmos15-MAT
| Id | Subject | Object | Predicate | Lexical cue | mat_id |
|---|---|---|---|---|---|
| T1 | 626-631 | Body_part | denotes | urine | http://purl.obolibrary.org/obo/MAT_0000058 |
GlyCosmos-GlycoEpitope
| Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
|---|---|---|---|---|---|
| T1 | 942-960 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | galactosylceramide | http://www.glycoepitope.jp/epitopes/EP0074 |
| T2 | 1349-1367 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | galactosylceramide | http://www.glycoepitope.jp/epitopes/EP0074 |
Anatomy-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 626-631 | Body_part | denotes | urine | http://purl.obolibrary.org/obo/UBERON_0001088 |
HP-phenotype
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 137-153 | Phenotype | denotes | leukodystrophies | HP:0002415 |
| T2 | 245-259 | Phenotype | denotes | leukodystrophy | HP:0002415 |